Background: Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen-related food allergy. We aimed to investigate the efficacy of oneyear AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birchrelated soya allergy. Methods: Of 138 subjects with Bet v 1 sensitization, 82 were positive at doubleblind placebo-controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per-protocol population (PPP) had received ≥150 lg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sIgE/IgG4 against Bet v 1 and Gly m 4. Between-group changes were investigated (ANCOVA, Mann-Whitney U-test, Fisher exact test). Results: Baseline characteristics including LOAELs were comparable in both groups with objS and subjS occurring in 82% and 95% of active (n = 38) vs 78% and 83% of placebo group (n = 18). After AIT, objS occurred in 24% and 47%, respectively. LOAEL group differences showed a beneficial tendency (P = 0.081) for LOAEL objective in PPP (30 active, 15 placebo). sIgG4 raised only in active group (Bet v 1: P = 0.054, Gly m 4: P = 0.037), and no relevant changes occurred for sIgE. Only 56% of the intended sample size was recruited.
Conclusion:
For the first time, we present data on the effect of rBet v 1-FV on birch-related soya allergy. rBet v 1-FV AIT induced significant immunogenic effects. Clinical assessment showed a tendency in favour of the active group but did not reach statistical significance.
Sensitization to major birch pollen allergen Bet v 1 is often associated with pollen-related food allergy (FA) (1) , and birch-related soya allergy became of growing importance during the last years (2) (3) (4) . The immunological basis for birch pollen-related FA results from IgE antibodies (ab) that are raised against major pollen allergens but that can also recognize homologous allergens belonging to the pathogenesisrelated protein family 10, for example Gly m 4 in soya bean (5) (6) (7) .
There is still controversy as to whether pollen-related FA can be successfully treated with allergen immunotherapy (AIT) with pollen allergens (8) (9) (10) (11) . As birch pollen AIT was shown to induce Bet v 1-specific (s) IgG4-ab that cross-reacts with related food allergens and inhibits IgE binding by epitope competition, clinical effects of AIT on pollen-related FA are to be expected (8, 12) .
Within previous investigations, birch pollen AIT with either sublingual (SLIT) or subcutaneous (SCIT) application improved pollen-related FA in some studies (13) (14) (15) (16) (17) , while others could not confirm this (18) (19) (20) . The studies that reported improvement (13) (14) (15) (16) (17) were not placebo-controlled and did not include double-blind placebo-controlled food challenge (DBPCFC) for endpoint assessment. The only existing randomized placebo-controlled trial investigated clinical effects of birch pollen AIT (single maximum dose 12.3 lg Bet v 1/ml (21)) on birch-related hazelnut FA by DBPCFC and was not able to detect group differences (19) . It was suggested that doses to induce an appreciable effect of birch pollen AIT on pollen-related FA should be higher than those sufficient to improve pollen-related respiratory symptoms (16, 18, 21) .
Because of the growing number of affected patients and increasingly frequent reports on severe reactions (2-4, 6), we decided to investigate the effect of rBet v 1-FV AIT (single maximum dose 80 lg/ml of Bet v 1/ml (22, 23) ) on birchrelated soya FA. The multicentric setting required previous standardization of DBPCFC with soya (24) .
Methods

Setting and patient selection
Between January 2010 and February 2013, 195 adults (18-65 years) with history of birch pollen allergy were recruited in 16 centres (15 German, one Swiss). They underwent standardized allergy interview, skin prick test (SPT) as well as serum IgE test (see Fig. 1 ). We defined eligibility for DBPCFC if patients had positive SPT for birch, ≥3.5 kU/l of sIgE for birch allergen Bet v 1 and ≥0.7 kU/l for its soya homologue Gly m 4 (Thermo Fisher, Freiburg, Germany). The trial (EudraCT-Nr.: 2009-011737-27) was approved by the competent authorities in Germany and Switzerland; the leading ethic committee was located at University Medical Centre Leipzig (UMCL). All patients provided written informed consent. Main exclusion criteria were pregnancy and unstable asthma. The following drugs were contraindicated during AIT: ongoing immunosuppression, long-term treatment with tranquilizers/psycho active drugs, betablocker, ongoing/previous anti-IgE therapy. The following drugs were allowed if needed: antihistamines, topical glucocorticosteroids, systemic glucocorticosteroids up to 7.5 mg prednisolone equivalent ≤5 days. A sample size of 97 subjects (with randomization ratio 2:1) was regarded sufficient to reach a study power of ≥90%, based on lowest observed adverse effect levels for objective signs (LOAEL obj ) and subjective symptoms (LOAEL subj ) as two primary endpoints without hierarchy. LOAELs (including their heterogeneity) as presented previously (4) were used for calculation of sample size, as well as clinically relevant group differences of 20 g in LOAEL obj , 10 g in LOAEL subj and 15% noncompliance/ dropout rate. NCSS/ PASS software was applied.
Skin prick test
At baseline, SPT was performed with commercially available supplement-free soya drinks (single prick to prick test, ALPRO, Uelzena, Germany) and with a panel of respiratory allergens including birch (Allergopharma GmbH & Co KG, Reinbek, Germany) for inclusion (cut-off >/=3 mm). Due to unexpected market withdrawal of the drink planned to be applied, only in case of comparable drinks used both before and following AIT, any reduction of wheal diameter at the end of treatment (as binary outcome) was analysed. Also, circle-approximated soya-induced wheal area was divided by that induced by histamine (histamine-adjusted soya reaction/ HASR) in analogy to Dreborg (25) .
Double-blind placebo-controlled food challenge
Standardization of DBPCFC including composition of CM with consistent Gly m 4 levels was previously described (24, 26) . Single dose levels of soya protein were 0.0004 -0.0044 -0.05 -0.15 -0.5 -1.5 -2.5 -5 -15 g with a maximum cumulative dose of 24.7 g protein. Investigators monitored 10 objective signs, and patients recorded eight subjective symptoms on 10-cm visual analogue scales (VAS) each. DBPCFC was stopped after dose level 9 or if the patient showed any objective symptoms before.
DBPCFC was defined positive if a patient presented at least one of the following reactions: >/=1 objective sign and/ or >/=1 subjective symptoms (VAS value reaching 1.5 cm or more and/or two or more subjective symptoms with single VAS values each reaching 0.5 cm or more and summing up to 4 cm or more in total) (24) .
LOAELs corresponding to minimal reactive/threshold dose for objective signs and subjective symptoms were determined. To be able to detect any postinterventional increase in symptom-eliciting doses, we only included patients for AIT in whom DBPCFC was judged as positive at dose level 7 (single dose 2.5 g, cumulative 4.7 g soya protein) or below. Postinterventional DBPCFC was performed within three months after end of AIT.
Laboratory investigations
sIgE-and sIgG4-ab were determined using ImmunoCAP (Thermo Fisher Scientific, Freiburg, Germany). At screening, sIgE-ab against Bet v 1 and Gly m 4 were measured for inclusion. sIgE-and sIgG4-ab (27) against birch allergens Bet v 1, Bet v 2, soya extract, the soya allergens Gly m 4, Gly m 5, Gly m 6, frequent birch-related food allergens Api g 1 (celery), Cor a 1 (hazelnut), Dau c 1 (carrot; made of equimolar ratio of Dau c 1.0104 and Dau c 1.0201), Mal d 1 (apple) and Pru av 1 (cherry) as well as sIgE against cross-reacting carbohydrate determinants (MUXF3) were investigated at different time (t) points: t1 -at first injection, t2 -at end of updosing, t3 -at start of maintenance therapy, t4 -at fourth dose and t5 -at last injection. Blood samples of all randomized subjects were shipped to Paul-Ehrlich-Institut, Langen, Germany, and stored at À80°C until assayed. Major protocol violation n = 7
PP population n = 30
No start of therapy n = 1
Placebo n = 18
Major protocol violation n = 2
PP population n = 15
End of study (abnormal laboratory values, withdrawal of consent or other reasons) n = 26
End of study (insufficient SPT/IgE-ab results, withdrawal of consent or other reasons) n = 57 Figure 1 CONSORT flow chart of patients through the study. Only patients with positive double-blind placebo-controlled food challenge (DBPCFC) with soya were eligible for randomization to either rBet v 1-FV (active) or placebo intervention. Of 56 patients randomized, 54 were started on interventional allergen immunotherapy.
Major protocol violations consisted in (i) violation of in/exclusion criteria (including baseline DBPCFC) and/or (ii) cumulative AIT dose applied ≤150 lg and/or (iii) missing data from postinterventional DBPCFC resulting in missing primary endpoints. They occurred in both groups and led to exclusion from per-protocol (PP) population.
Allergy 72 . During updosing, injections were administered at one-weekly interval, with a maximum single dose of 80 lg. During prolongation, there were gradually increased injection intervals from 7 to 28 days. During maintenance, injections were applied every 28 days with a 50% reduction during the birch pollen season. Asthma patients were monitored with peak flow at each trial injection. Patients of per-protocol set population (PPP) had received a cumulative dose of at least 150 lg major allergen (or placebo equivalent).
Outcome measures
Primary endpoints were DBPCFC-based LOAELs LOAEL obj and LOAEL subj . Additionally, occurrence of any objective signs or subjective symptoms at postinterventional DBPCFC was investigated. Secondary endpoints were (i) courses of sIgEand sIgG4-ab levels for Bet v 1, Gly m 4 and other birchrelated foods from baseline to end of treatment, (ii) pre-post changes of reactivity at SPT (if suitable) as well as (iii) pre-post changes of FA-related quality of life (QoL) via FA quality of life questionnaire -adult form (FAQLQ-AF) (28, 29) .
Statistics
The confirmatory analysis was based on the full analysis set (FAS) with baseline LOAEL instead of missing values at end of study if applicable and intention-to-treat principle. We focused on two primary endpoints without hierarchy -both LOAEL obj and LOAEL subj as it was unclear in advance how many patients would react with objective signs at DBPCFC. Postinterventional measures after the ingestion of soya-containing CM were used in nonparametric analysis of covariance (ANCOVA) with corresponding baseline measures as covariates (30) . The global significance level of the clinical trial was limited to a = 5%. The testwise a-levels were adjusted for multiplicity according to the Bonferroni-Holm method (31) based on the ordered P values observed. The smaller observed P-values P(1) (corresponding with either LOAEL obj or LOAEL subj ) had to be lower than/equal to a(1) = a global / 2 = 0.025 ≥ P(1) to identify a significant treatment effect in at least one LOAEL. For the 2nd comparison, P(2) ≤ a(2) = 0.05 should be observed to establish significance in both endpoints. SAS macros developed and provided by the University of G€ ottingen within the German Research Foundation (DFG)-sponsored project 'Ordinal Data' were used to compare the treatments without any further covariates in confirmatory analysis. In a planned sensitivity analysis, the same procedures as in confirmatory analysis were applied within the per-protocol population (PPP). Secondary and safety outcomes were analysed by Fishers exact test, repeated-measures ANCOVA and Mann-Whitney U-test, with neither adjustment for multiplicity nor missing value imputations.
Results
Characteristics of screening and study population
A total of 195 patients (63.4% female, mean (SD) age 38.1 (12.8) years) were screened. A total of 138 patients were eligible for DBPCFC, and 82 (59.4%) had positive DBPCFC at baseline (24) . Of those 82, 56 patients were randomized (2:1) to interventional AIT with rBet v 1-FV (n = 38) or placebo (n = 18) (Fig. 1) . A total of 19 of 38 (50%) and eight of 18 (44%) had a history of previous reactions to any soya product. A total of 13 of 38 (34%) and eight of 18 (44%) underwent a previous AIT. Table 1 contains major characteristics of the trial population. A total of 54 of 56 randomized patients started the intervention, meaning that only 56% (54/ 97) of the intended sample size could be recruited within the given time frame. Major protocol violations occurred in nine of 54 subjects: in the active group, two subjects did not fulfil criteria for positive DBPCFC and in three other, cumulative AIT allergen doses applied were below 150 lg. In four subjects of active and two from placebo group, no postinterventional DBPCFC was performed. PPP included 45 subjects (for details, see Table 1 ).
Allergen immunotherapy and adverse events
Maintenance phase was reached in 31 of 37 (84%) patients of active and in 16 of 17 (94%) of placebo group. Cumulative allergen doses are given in Table 1 . During treatment course, 119 injection-related adverse events (AE) occurred in 22 of 37 (60%) patients of the active and in nine of 17 (53%) of the placebo group. AEs were almost exclusively mild: 64 of 119 (54%) consisted of localized injection site reactions, 13 of 119 (11%) were skin reactions with generalized urticaria in one subject, 15 of 119 (13%) had respiratory (nose/lung; three asthmatic responses in two patients), seven of 119 (6%) eye and 20 of 119 (17%) unspecific symptoms. There were no injection-related serious AEs. During AIT, systemic intake of antihistamines was documented in 21 of 54 (39%) and of short-term systemic glucocorticosteroids in eight of 54 (15%) subjects (due to skin lesions in n = 6 or asthma in n = 2).
Double-blind placebo-controlled food challenges
At baseline, objective signs were present in 45 of 56 (80%): blistering/swelling of oral mucosa 47% (21 of 45), flush 18%, urticaria 2%, angioedema 7%, conjunctivitis 18%, rhinitis 18%, peakflow reduction 9%, heart rate increase 9%, drop in blood pressure 2%, gastrointestinal symptoms 4%. Subjective symptoms occurred in 51 of 56 (91%); most frequently reported were oral tingling/blistering 34% (19 of 56), dysphagia 23% and itching 14%. Nausea, abdominal pain and dizziness occurred in 7%, respectively, dyspnoea in 4% and perceived lip swelling in 2%. Cumulative doses at occurrence of first symptoms and signs are shown in Fig. 2 , and DBPCFC-based outcome measures are listed in Table 2 . No relevant dysbalances were seen between both groups at baseline with regard to LOAELs, type of objective signs or type of subjective symptoms. In confirmatory analyses, in PPP (but not in FAS), LOAE-L obj tended to be higher in the active group (treated with rBet v 1-FV) compared with the placebo group (P = 0.081). Individual dose-level changes are shown in Fig. 3 . With the best/worst case group-related observations (regarding between-group differences, heterogeneity and LOAEL obj as exclusive primary endpoint), we calculated that between 81 and 162 patients (best/worst case scenario) would have been necessary to provide significant test results. A postinterventional increase in one dose level or more occurred in 20 of 26 (77%) subjects of active and in nine of 14 (64%) subjects of placebo group who presented with objective signs both at baseline and postintervention. 8.0 mm [6.9;9.6], respectively. In the randomized population, the same type of soya drink at baseline and at control was used in 43 of 54 (80%) of subjects, and in PPP, in 26 of 30 (87%) of active and in 14 of 15 (93%) of placebo group. In PPP, there was a nonsignificant (P = 0.116) shift towards reduced soya-induced wheal diameter in active (6.0 mm) compared with placebo group (7.3 mm) at postinterventional SPT. HASR changed from 3.27-fold area (SD 4.48) at baseline to 1,57-fold (1.1) postintervention in the active, and from 2.33-fold (1.46) to 2.89-fold (3.71) in the placebo group, respectively. No significant between-group differences were found, although a descriptive change towards smaller HASR was observed within the rBet v 1-group compared to unchanged reactivity in the placebo group.
Skin prick test
Laboratory investigations
At baseline, sIgE-ab >0.35 kU/l against Cor a 1, Dau c1, Mal d1, Pru av1 was detected in all subjects, against Api g 1 in 51 of 54, against soya bean extract in 10 of 54, against Bet v 2 in five of 54 and against MUXF3 in four of 54. Lowlevel Gly m 5 and low-level Gly m 6 sIgE were seen exclusively in one patient (0.52 and 0.99 kU/l, respectively). At baseline (t1), no relevant group differences were shown for any sIgE-ab investigated. In neither group, courses of sIgE-ab showed significant differences from t1 to t5 for Bet v 1, Gly m 4 or any other allergen investigated.
In the active, but not in the placebo group, a significant increase from t1 to t5 for sIgG4-ab against Bet v 1 (Fig. 4A,  B) , Gly m 4 (Fig. 4C) , Cor a 1 (Fig. 4D) , Api g 1 (P < 0.0001; respectively), Dau c1 (P < 0.001), Mal d 1 (P > 0.006) and Pru av 1 (P < 0.015) was found. When comparing postinterventional t5 values, there was a significant increase in sIgG4-ab against Gly m 4 (P = 0.037) and Cor a 1 (P = 0.033) in the active group; borderline significant increases occurred for sIgG4-ab against Bet v 1 (P = 0.054), Bet v 2 (P = 0.074), Pru av 1 (P = 0.088) and Mal d 1 (P = 0.06). No significant differences were seen for IgG4-ab against Gly m 5, Gly m 6, soya bean extract, CCD, Api g1, Dau c 1.
Quality of life
FAQLQ-AF scores at baseline are given in Table 1 . No significant differences between active and placebo group were found with nearly unchanged postinterventional scores.
Discussion
The BASALIT trial is the first randomized, double-blind placebo-controlled trial evaluating the efficacy of a componentbased birch pollen AIT on birch-related soya FA in a multicentre setting. The immunological basis for this type of FA results from Bet v 1 homologous soya allergen Gly m 4 which shows 53% amino acid sequence identity and 63% sequence peptide similarity to Bet v 1 (5, 6) . Subjects with combined Bet v 1 and Gly m 4 sensitization were included. Even though IgE values cannot safely predict reactivity at DBPCFC (32, 33), we initially decided to only include patients with defined IgE cut-off values. The rBet v1-FV extract was chosen for AIT as it shows low IgE binding (22, 23, 34) , was well tolerated in higher doses with no increase in adverse effects compared with the native extract and induced a significant increase in birch pollen sIgG4-ab (22, 23, 35) .
A main limiting factor for investigations on FA is the availability of standardized CM with standardized allergen content to be used within DBPCFC. For this trial, we set up standardized soya CM with consistent levels for protein contents and Gly m 4 levels (24, 26) . Also, a standardized evaluation system was established (24) . Despite intensified efforts, we only reached 56% of the intended sample size within the given time frame.
The rBet v 1-FV extract was well tolerated, and, as in previous trials (22, 35) , the safety profile was comparable with placebo; no rBet v 1-FV-related severe adverse effects occurred. Subjects of active group had received cumulative Bet v 1 allergen doses being eight-to 20-fold higher compared with previous AIT studies on pollen-related FA (i.e. 50 lg (18) and 150 lg (12)).
LOAEL obj at postinterventional DBPCFC tended to be higher in active compared with placebo group in per-protocol population. In detail, at baseline, DBPCFC objective signs occurred in 82% of active vs 78% of placebo group and at postinterventional DBPCFC in only 23% vs 47%. No Number of patients Cumulative soya protein per dose level (g)
Objective signs Subjective symptoms Figure 2 Cumulative eliciting doses of soya protein at occurrence of first objective signs and first subjective symptoms at baseline double-blind placebo-controlled food challenge (DBPCFC). All 56 subjects were DBPCFC positive at baseline according to predefined criteria, with 80% experiencing objective signs and 91% subjective symptoms in detail. Data presented for both interventional groups (including primary endpoints) with median values [interquartile range] of lowest observed adverse effect levels for objective signs and subjective symptoms (LOAEL obj/subj ); no significant group differences after SCIT (* in per-protocol population [PPP] between-group effect for treatment with P-value = 0.081) were observed.
significant differences were seen with regard to LOAEL subj or any overall occurrence of subjective symptoms between groups. Possibly, effects could have been more pronounced by applying higher soya allergen doses, as only 80% of all subjects presented with objective signs at baseline DBPCFC. Allergen doses were comparable to those having been reported in a previous trial, where, however, another food matrix had been applied (4). In the active group, some subjects showed postinterventional decrease in LOAEL, while remarkably, in the placebo group, a LOAEL increase was not rare (Fig. 3) . One might speculate that there is a fluctuating course of the pollenrelated FA being influenced not only by birch pollen season but also by other clinical cofactors that might not have been fully eliminated at some time points of DBPCFC.
In vitro investigations indicated an immunogenic effect of the rBet v 1-FV extract as there was a significant increase in Bet v 1 sIgG4-ab in active group which was more than twice as high as in previous trials using birch allergen extracts with lower Bet v 1 allergen levels (12, 15) . Despite a significant increase in sIgG4-ab to all Bet v 1 homologues investigated, we noticed significant between-group effects only for sIgG4-ab against Gly m 4 and Cor a 1. However, sIgG4-ab against Bet v 1, Bet v 2, Pru av 1 and Mal d 1 tended to be higher in rBet v 1-FV group.
In accordance with our data, an increase in sIgG4-ab against Bet v 1 and Cor a 1 was demonstrated in another trial investigating the effect of one-year whole extract birch pollen-SCIT in birch-related hazelnut allergy (19) . Even though sIgG4-ab was expected to be functionally blocking, authors failed to show clinical improvement of hazelnut allergy after one year of treatment (19) .
In another recent trial, authors discussed that birch pollen AIT may induce Bet v 1 sIgG4-ab that cross-reacts with related food allergens Mal d 1 and Cor a 1 and inhibits sIgE binding by epitope competition (12) . This effect was detectable after one year but was even stronger after three years of AIT (cumulative allergen dose 500 lg) (12) , and reduction in food allergen-reactive sIgE-ab started only later than 12 months of AIT. Interestingly, sIgG4-ab was not simply IgE epitope identical as more than 35% of predicted IgE epitopes of Bet v 1, Mal d 1 and Cor a 1 were not recognized by sIgG4-ab. It was concluded that SCIT-induced sIgG4-ab may not cover all IgE specificities (12) .
Due to unexpected market withdrawal, the soya drink being scheduled for baseline and control SPT was only available in a subgroup of patients. Therefore, we were not able to finally assess the influence of AIT on soya-induced wheal diameter or on histamine-adjusted wheal area (25, 36) .
Finally, in our trial, a rather small impact of birch-related FA on QoL was measured which confirmed a previous single-centre experience (29) .
In summary, for the first time, we present data on the effect of AIT with the major birch pollen allergen Bet v 1 on birch pollen-related FA to soya. This is the only study having investigated AIT-induced changes in FA symptoms by means of standardized food challenge procedures and CM with consistent soya allergen levels (24, 26) . One-year SCIT with rBet v 1-FV showed a clear immunogenic effect on sIgE-and sIgG4-ab against Bet v 1 and Bet v 1 homologous food allergens. Clinical assessment showed a tendency in favour of the active group but did not reach statistical significance. One reason may be that the treatment period was too short to induce changes on relevant antibody levels, on epitopes or on clinical symptoms. Another reason lies in the fact that we failed to recruit the intended study sample size and, therefore, conclusive clinical results could not be reached.
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